Physiological levels of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity

What is it about?

Our findings point to a novel cardioprotective role for circulating CgA against doxorubicin-induced cardiotoxicity. Monitoring plasma levels of CgA and/or its fragments before and after chemotherapy in cancer patients might provide important prognostic information regarding drug-related cardiotoxicity. Furthermore, administration of exogenous CgA to patients might represent a novel pharmacological strategy to limit cardiac damage typically associated with anthracycline therapy, particularly in patients with reduced plasma levels of this protein.

Featured Image